Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;24(1):43-50.
doi: 10.1007/s11886-021-01622-z. Epub 2022 Jan 13.

Updates in Cerebral Venous Thrombosis

Arshia Alimohammadi  1   2 , Diana J Kim  1   3 , Thalia S Field  4   5   6
Affiliations
Review

Updates in Cerebral Venous Thrombosis

Arshia Alimohammadi et al. Curr Cardiol Rep. 2022 Jan.

Abstract

Purpose of review: Cerebral venous thrombosis (CVT) is a rare cause of stroke that most commonly affects younger women. Here, we review new literature relevant to the management and prognosis of individuals with CVT and ongoing areas of uncertainty.

Recent findings: Direct-acting oral anticoagulants (DOACs) are being increasingly integrated into routine care but are not yet recommended by guidelines. Recent randomized clinical trials and available case series offer reassuring safety data. Routine use of endovascular therapy is not associated with improved outcomes. The relationship between recanalization and prognosis is uncertain. The evidence base for management of CVT continues to improve. Ongoing areas of uncertainty include duration of therapy and whether certain subgroups of patients may benefit from neurointervention or personalized approaches to antithrombotic strategy. The state of knowledge will continue to benefit from large collaborative international efforts, and integration of patient partnerships to identify research priorities.

Keywords: Anticoagulation; Cerebral venous thrombosis; DOAC; Endovascular therapy; Prognosis; Recanalization.

PubMed Disclaimer

Conflict of interest statement

Dr. Field is PI for the SECRET (Study of rivaroxaban for ceREbral venous Thrombosis) trial and receives in-kind study medication from Bayer Canada for the study. She is supported by the Vancouver Coastal Health Research Institute, the Michael Smith Foundation for Health Research, the Heart and Stroke Foundation of Canada. The other authors declare that they have no conflict of interest.

References

    1. Bousser M-G, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol. 2007;6:162–170. - PubMed
    1. Shatzel JJ, O’Donnell M, Olson SR, Kearney MR, Daughety MM, Hum J, et al. Venous thrombosis in unusual sites: a practical review for the hematologist. Eur J Haematol. 2019;102:53–62. - PubMed
    1. Canhão P, Ferro JM, Lindgren AG, Bousser M-G, Stam J, Barinagarrementeria F, et al. Causes and predictors of death in cerebral venous thrombosis. Stroke. 2005;36:1720–1725. - PubMed
    1. Coutinho JM, Ferro JM, Canhão P, Barinagarrementeria F, Cantú C, Bousser M-G, et al. Cerebral venous and sinus thrombosis in women. Stroke. 2009;40:2356–2361. - PubMed
    1. Koopman K, Uyttenboogaart M, Vroomen PC, van der Meer J, De Keyser J, Luijckx G-J. Long-term sequelae after cerebral venous thrombosis in functionally independent patients. J Stroke Cerebrovasc Dis. 2009;18:198–202. - PubMed

MeSH terms